Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 190.12

-2.5%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: buyhiman who wrote (16566)	3/5/1998 4:42:00 PM
From: Henry Niman	Read Replies (1) of 32384

Carl, There have been many correlative studies that show benefits of estrogen in preventing Alzheimer or improving memory. A recent report found a correlation with the size (small) of the cholea and a tendency of females to be gay. The size is determined in utero by hormones (androgens). Thus it seems highly likely that hormones can have an influence. LGND apparently plans on using designer estrogens to get the benefits of estrogen (delaying or preventing Alzheimers and improving memory), without the side effects (stimulate uterine tissue in females and feminizing effects in males). LGND has extensive programs in that area (PFE's Droloxifene and CP-366,156 are in the clinic while AHP's TSE424 is slated to enter the clinic this month). Moreover, LGND has a research program with LLY to investigate the enhancing effect that rexinoids (Targretin) have on designer estrogens (Evista). Thus, any of the above designer estrogens may have a positive effect on the CNS, and such an effect could be potentiated by rexinoids. Vilar headed up AHP's Premarin program, so I'm sure that he is interested. Since Premarin is a $1 Billion drug, I'm sure that AHP is interested also.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next